Highly Regarded Life Sciences Team of 18 Attorneys Led by Peter Corless, David Conlin, Kathleen Carr and Kongsik Kim Joins Mintz Boston Office

A group of top intellectual property attorneys specializing in life sciences headed up by David Conlin, Peter Corless, Kathleen Carr and Kongsik Kim has joined Mintz, Cohn, Ferris, Glovsky and Popeo, P.C. from Edwards Wildman. Based in Boston, the group, which includes eight Members, three Of Counsel and seven Associates, further expands the firm’s highly recognized patent prosecution and litigation capabilities, particularly in the life sciences and pharmaceutical sectors.

“The addition of this exemplary group further bolsters our national and international IP capabilities, adding substantial breadth and depth to our life sciences and corporate practices,” said Bob Bodian, Managing Member of Mintz.

“From generic pharmaceutical challenges to regulatory and legislative changes and shifts in IP policy and law, life sciences and pharma companies are facing mounting challenges with respect to establishing, managing and protecting their intellectual property,” said Michael Renaud, Division Head and a Member of the Intellectual Property Section at Mintz. “This distinguished group includes some of the most accomplished IP attorneys in the field, with robust backgrounds in patent prosecution and litigation that will complement our capabilities and further strengthen the level of service and expertise we are able to deliver to clients.”

“Mintz has among the strongest intellectual property capabilities of any full service law firm in the country,” said Peter Corless. “We are thrilled to be joining this talented team and are excited for the opportunity to leverage and grow the firm’s well established platforms to the benefit of clients.”  
 
The new Members joining Mintz include:

Peter Corless.  Former Co-Chair of the Edwards Wildman Patent Practice Group.  Mr. Corless has prepared, prosecuted and managed patent portfolios for myriad organizations worldwide. His clients include research institutions; Global 1000 manufacturing, chemical and pharmaceutical companies; emerging biotechnology and small molecule pharmaceutical companies; medical device companies; and firms championing mechanical and electro-mechanical innovations, especially those related to the automotive industry. A former synthetic organic chemist, he also brings to the firm experience as an inventor on U.S. Patent 4,977,173, which covers predecessor development compounds to Pfizer’s oxazolidinone antibacterial Zyvox, now in clinical use.

David Conlin.  Former Co-Chair of the Edwards Wildman Intellectual Property Litigation Group. Mr. Conlin has obtained and litigated many key patents and has successfully concluded multinational licensing arrangements for clients across myriad industries, including pharmaceuticals, biotechnology, electronics, electro-mechanical technologies and software technologies. He is a former chemical engineer and patent examiner, and served as a technical advisor to the U.S. Court of Customs and Patent Appeals, predecessor court to the Federal Circuit.  Mr. Conlin was named Boston Patent Attorney of the Year in 2014 by Best Lawyers/U.S.News and has been listed in Best Lawyers in America for many years.

Kathleen Carr.  Former Co-Chair of the Edwards Wildman Intellectual Property Litigation Group. Ms. Carr has served as lead counsel on many cases, and has led trial teams in major pharmaceutical patent litigation. She has successfully argued before the First Circuit, and prevailed in appeals before the Federal Circuit. Ms. Carr’s clients include large corporations, start-ups and individuals involved in patent, trademark, and copyright matters, licensing negotiation and dispute resolution, and arbitration and mediation, in technologies such as pharmaceuticals, biotechnology, mechanical devices, computers, business methods, printers, photocopiers and design patents. 

Kongsik Kim.  An expert on all aspects of IP procurement and enforcement, including patents, trademarks and copyrights, Mr. Kim’s practice covers chemistry, biochemistry, pharmaceuticals, chemical engineering, biochemical engineering, agricultural/food biotechnology, biomedical engineering, enzyme technology, environmental engineering, polymer engineering, semiconductor technology, LED/LCD technology, fuel cell technology, solar energy and green technology, automobiles, medical devices, test/measuring instruments and computer software.  In addition to being registered before the USPTO, Mr. Kim is a registered Korean Patent Attorney.  He regularly advises Korean institutions on cross-border transactions and multinational patent portfolios.

David Cotta.  A patent litigator comfortable working in a broad range of technologies, Mr. Cotta has represented major pharmaceutical companies in Hatch-Waxman litigations involving pharmaceutical compounds, formulations, and methods of use.  Other cases have involved blood screens, immunoassays, mass spectrometers, alloys, automotive parts, consumer products, lithographic developers, and bacteria detection media.

Steven Jensen.  Specializing in U.S. and foreign patent applications in the mechanical, electrical, computer, and materials science arts, Mr. Jensen focuses on inventions in the fields of semiconductor devices, manufacturing systems, liquid crystal display circuits, medical devices, business methods and computer hardware and software. He also prepares infringement and validity opinions, and provides litigation support and infringement/validity analysis for various technologies. He has argued successfully before the U.S. Board of Patent Appeals and Interferences, and has served as a Patent Examiner at the U.S. Patent and Trademark Office.

Adam Samansky.  An IP litigation specialist focused on patent, trademark, and trade secret law, and complex technologies in the pharmaceutical, medical, high technology and defense industries, Mr. Samansky has extensive trial experience before multiple U.S. District Courts, and maintains an active practice before the U.S. Court of Appeals for the Federal Circuit and the U.S. Supreme Court. He routinely consults on blockbuster pharmaceutical assets, including the review and assessment of litigation, regulatory and settlement strategies. He also advises private investors on high-stakes IP litigation at both the trial and appellate level.

Tom Wintner.  A highly successful litigator, Mr. Wintner has tried cases in both state and federal court and has shepherded others through mediation or arbitration. On the appellate side, he has secured victories in the First, Fourth, Ninth, and Federal Circuit Courts of Appeal, as well as the Massachusetts Appeals Court. He draws on his experience as a former research chemist in his work with pharmaceutical and biotech firms. As a former dean at Williams College, he often represents colleges and universities in matters as diverse as faculty and staff employment, campus security, regulatory compliance and internal investigations.